Mentioned in ?
References in periodicals archive ?
DRUG company ProStrakan Group yesterday sold their acne gel Zindaclin to Crawford Healthcare.
Zindaclin was the first product Galashiels firm ProStrakan developed and was launched in the UK in 2002.
Zindaclin, a unique, once-a-day clindamycin-based gel for the treatment of acne, has been in-licensed from UK based Strakan Pharmaceuticals.
The size of the anti-acne market in Australia for Zindaclin is estimated to be worth approximately A$12 million.
A new treatment has just become available on prescription (Zindaclin) which only has to be applied to the skin once a day (rather than twice as with existing creams and lotions) and this may be more helpful for teenagers.